Cargando…
一代与二代酪氨酸激酶抑制剂联合化疗序贯异基因造血干细胞移植治疗Ph(+)急性淋巴细胞白血病疗效比较
OBJECTIVE: To investigate the efficacy of sequential treatment with first-line administration of second-generation tyrosine kinase inhibitors (TKI) and first-generation TKI (imatinib) in patients with Ph(+) acute lymphoblastic leukemia (Ph(+) ALL) followed by allogeneic hematopoietic stem cell trans...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Editorial office of Chinese Journal of Hematology
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342571/ https://www.ncbi.nlm.nih.gov/pubmed/29562444 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.02.007 |
Ejemplares similares
-
一代与二代酪氨酸激酶抑制剂为基础的方案治疗BCR-ABL阳性急性淋巴细胞白血病疗效比较
Publicado: (2019) -
酪氨酸激酶抑制剂联合化疗后行异基因造血干细胞移植治疗Ph(+)急性淋巴细胞白血病与异基因造血干细胞移植治疗Ph(−)急性淋巴细胞白血病的疗效比较
Publicado: (2015) -
非小细胞肺癌脑转移患者接受一代表皮生长因子受体酪氨酸激酶抑制剂治疗的临床研究
Publicado: (2017) -
新酪氨酸激酶抑制剂BGJ398对白血病细胞株KG-1细胞的抑制效应研究
Publicado: (2018) -
酪氨酸激酶抑制剂耐药机制及其治疗策略
Publicado: (2011)